Moreover, two RET inhibitors (selpercatinib and pralsetinib) were registered in NSCLC patients with RET gene rearrangements, and two NTRK inhibitors (larotrectinib and entrectinib) in patients with NTRK1, NTRK2 or NTRK3 gene rearrangements. Here, RET is linked to non-small cell lung carcinoma.